Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 423

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 7
Chunk 423
---
10-K for the year ended December 31, 2023, which was filed with the SEC on July 18, 2025 and incorporated herein by reference.(3)Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the SEC on August 13, 2020 and incorporated herein by reference..

Item 16. FORM 10-K SUMMARY

Not applicable

 28Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACRO BIOMEDICAL CO., LTD. Date: July 24, 2025By:/s/ Pao-Chi Chu Name:Pao-Chi Chu Title:Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. 

SignatureTitleDate/s/ Pao-Chi ChuDirector, chief executive officer and July 24, 2025Pao-Chi Chuchief financial officer (principal executive, financial and accounting officer)

 29Table of Contents

ACRO BIOMEDICAL CO., LTD.

Index to Financial Statements

 Page Reports of Independent Registered Public Accounting Firms (PCAOB ID 2851) F-2 Balance Sheets at December 31, 2024 and 2023 F-3 Statements of Operations for the years ended December 31, 2024 and 2023  F-4 Statements of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023  F-5 Statements of Cash Flows for the years ended December 31, 2024 and 2023  F-6 Notes to Financial Statements F-7

 F-1Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Stockholders and Board of Directors of

Acro Biomedical Co., Ltd.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Acro Biomedical Co., Ltd. (the “Company") as of December 31, 2024 and 2023, and the related statements of operations, changes in stockholders' equity